A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

被引：5
|
作者：
Ong, Faustine [1 ]
Short, Nicholas [2 ]
Daver, Naval [2 ]
Kadia, Tapan M. [2 ]
DiNardo, Courtney D. [2 ]
Yilmaz, Musa [2 ]
Alvarado, Yesid [2 ]
Vaughan, Kenneth [2 ]
Pierce, Sherry A. [2 ]
Kantarjian, Hagop [3 ]
Garcia-Manero, Guillermo [2 ]
Ravandi, Farhad [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Div Canc Med, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159110
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
615
引用
收藏
页码：9029 / 9031
页数：3
相关论文
共 50 条
  • [21] Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
    Sugamori, Haruko
    Lee, Takumi
    Mitomi, Takeshi
    Yamagishi, Chika
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (07) : 758 - 765
  • [22] Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
    Short, Nicholas J.
    Daver, Naval
    Dinardo, Courtney D.
    Kadia, Tapan
    Nasr, Lewis F.
    Macaron, Walid
    Yilmaz, Musa
    Borthakur, Gautam
    Montalban-Bravo, Guillermo
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Chien, Kelly S.
    Jabbour, Elias
    Nasnas, Cedric
    Huang, Xuelin
    Qiao, Wei
    Matthews, Jairo
    Stojanik, Christopher J.
    Patel, Keyur P.
    Abramova, Regina
    Thankachan, Jennifer
    Konopleva, Marina
    Kantarjian, Hagop
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (13) : 1499 - 1508
  • [23] Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML
    Yilmaz, Musa
    Kantarjian, Hagop
    Short, Nicholas J.
    Konopleva, Marina
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Maiti, Abhishek
    Jabbour, Elias J.
    Issa, Ghayas C.
    Jain, Nitin
    Takahashi, Koichi
    Sasaki, Koji
    Ohanian, Maro
    Tang, Guilin
    Loghavi, Sanam
    Patel, Keyur
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Ravandi, Farhad
    Daver, Naval
    BLOOD, 2021, 138
  • [24] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
    Hosono, Naoko
    Yokoyama, Hisayuki
    Aotsuka, Nobuyuki
    Ando, Kiyoshi
    Iida, Hiroatsu
    Ishikawa, Takayuki
    Usuki, Kensuke
    Onozawa, Masahiro
    Kizaki, Masahiro
    Kubo, Kohmei
    Kuroda, Junya
    Kobayashi, Yukio
    Shimizu, Takayuki
    Chiba, Shigeru
    Nara, Miho
    Hata, Tomoko
    Hidaka, Michihiro
    Fujiwara, Shin-Ichiro
    Maeda, Yoshinobu
    Morita, Yasuyoshi
    Kusano, Mikiko
    Lu, Qiaoyang
    Miyawaki, Shuichi
    Berrak, Erhan
    Hasabou, Nahla
    Naoe, Tomoki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2131 - 2141
  • [25] Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
    Smith, Catherine C.
    Levis, Mark J.
    Perl, Alexander E.
    Hill, Jason E.
    Rosales, Matt
    Bahceci, Erkut
    BLOOD ADVANCES, 2022, 6 (07) : 2144 - 2155
  • [26] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
    Naoko Hosono
    Hisayuki Yokoyama
    Nobuyuki Aotsuka
    Kiyoshi Ando
    Hiroatsu Iida
    Takayuki Ishikawa
    Kensuke Usuki
    Masahiro Onozawa
    Masahiro Kizaki
    Kohmei Kubo
    Junya Kuroda
    Yukio Kobayashi
    Takayuki Shimizu
    Shigeru Chiba
    Miho Nara
    Tomoko Hata
    Michihiro Hidaka
    Shin-Ichiro Fujiwara
    Yoshinobu Maeda
    Yasuyoshi Morita
    Mikiko Kusano
    Qiaoyang Lu
    Shuichi Miyawaki
    Erhan Berrak
    Nahla Hasabou
    Tomoki Naoe
    International Journal of Clinical Oncology, 2021, 26 : 2131 - 2141
  • [27] Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia
    Hirose, Natsuki
    Tachibana, Takayoshi
    Izumi, Akihiko
    Sato, Shuku
    Tadera, Noriyuki
    Tamai, Yotaro
    Kanamori, Heiwa
    Tanaka, Masatsugu
    Nakajima, Hideaki
    HEMATOLOGY, 2023, 28 (01)
  • [28] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Masamichi Mori
    Naoki Kaneko
    Yoko Ueno
    Masaki Yamada
    Ruriko Tanaka
    Rika Saito
    Itsuro Shimada
    Kenichi Mori
    Sadao Kuromitsu
    Investigational New Drugs, 2017, 35 : 556 - 565
  • [29] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [30] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Mori, Masamichi
    Kaneko, Naoki
    Ueno, Yoko
    Yamada, Masaki
    Tanaka, Ruriko
    Saito, Rika
    Shimada, Itsuro
    Mori, Kenichi
    Kuromitsu, Sadao
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565
12345